BioStem Technologies Inc (OTC: BSEM) Stock In Focus After Notice of Allowance for U.S. Patent Application
If you are looking into medical technology companies this morning then BioStem Technologies Inc (OTC: BSEM) could be the one to watch given yesterday’s events. The company came into focus after it announced a new positive development about one of its patents.
New Patent Allowance
The company announced that it had been granted a Notice of Allowance by the USPTO (United States Patent and Trademark Office) for a patent. The patent in question is titled “STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON.”
It was a significant new development for the company since it was going to be used by BioStem Technologies in developing unique allografts designed for the purpose of new age wound care through its own BioETrain process.
Further Information
It was also noted that the allografts developed through the new technology that would open up in order to enable exudates escape without causing any change in the surface area. As a consequence, the allografts would be idea for both chronic as well as acute wounds. The company also noted in the news release that the technology was unique and there was nothing similar in the market at this point in time.
CEO Quote
Jason Matuszewski, Chief Executive Officer of BioStem, stated: “BioStem continues to drive innovation in the wound care space, and we are pleased to enhance our intellectual property portfolio with the issuance of this significant patent. This is the first and only patent granted for use in tabular fenestrated allografts, which will support our commercial efforts and expands our IP portfolio. With 27 patents pending and 42 issued, BioStem has a strong portfolio across the wound care landscape that will protect the company as we advance in the market.”